News | December 11, 2007

PET/CT Imaging Proves Trustworthy for Detecting Cancer in Children

December 12, 2007 - According to research published in the December issue of the Journal of Nuclear Medicine, PET/CT imaging exhibits significantly higher sensitivity, specificity and accuracy than conventional imaging when it comes to detecting malignant tumors in children, and provides doctors with additional information about cancer in children, possibly sparing young patients from being overtreated.

The study found that PET/CT can detect small lymph node lesions diagnosed as negative with conventional (or anatomical) imaging and deny the presence of active disease in soft-tissue masses post-treatment, especially in children with a wide range of malignant cancers.

Researchers reviewed 151 FDG PET/CT exams that were performed on 55 children with noncentral nervous system malignancies (30 patients had lymphoma, cancer that affects the body's lymph nodes and other organs that are part of the body's immune and blood-forming systems).

According to the study, PET with CT imaging, with the radiotracer fluorodeoxyglucose (FDG) enables the collection of both biological and anatomical information during a single exam, with PET picking up metabolic signals of body cells and tissues and CT offering a detailed map of internal anatomy. When there were discrepancies between PET/CT and conventional anatomical imaging in analyzing cancer lesions, PET/CT was diagnostically accurate 90 percent of the time. Doctors monitor the radiation dose given to children in imaging exams, generally using lower doses than that of adult patients, to get adequate exam results,

The study says PET is a powerful molecular imaging procedure that noninvasively demonstrates the function of organs and other tissues. When PET is used to image cancer, a radiopharmaceutical (such as FDG, which includes both a sugar and a radionuclide) is injected into a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is drawn in higher amounts to cancerous areas. PET scans show where FDG is by tracking the gamma rays given off by the radionuclide tagging the drug and producing three-dimensional images of their distribution within the body. PET/CT offers precise fusion of metabolic PET images with high-quality anatomical CT images.

For more information: www. snm.org

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init